

# 1 Prevalence of Isolated Systolic Hypertension among People with 2 Diabetes in Indonesia

3 Mahalul Azam,<sup>1</sup> Fetty Nur Hidayati,<sup>1</sup> Arulita Ika Fibriana,<sup>1</sup> Udin Bahrudin,<sup>2</sup> Syed Mohamed  
4 Aljunid<sup>3</sup>

5 <sup>1</sup>Department of Public Health, Faculty of Sports Science, Universitas Negeri Semarang,  
6 Semarang, Indonesia

7 <sup>2</sup>Department of Cardiology and Vascular Medicine, Faculty of Medicine, Diponegoro  
8 University, Semarang, Indonesia

9 <sup>3</sup>Department of Health Policy and Management, Faculty of Public Health, Kuwait University,  
10 Kuwait, Kuwait

11 Correspondence should be addressed to Mahalul Azam; mahalul.azam@mail.unnes.ac.id

## 12 Abstract

13 The present study aimed to explore the prevalence of isolated systolic hypertension (ISH) and  
14 its risk factors among diabetes mellitus (DM) subjects in the community setting study in  
15 Indonesia. This cross-sectional study extracted secondary data from basic health survey  
16 (Riset Kesehatan Dasar; RISKESDAS) conducted in 2018. DM subjects were defined based  
17 on fasting blood glucose level  $\geq 126$  mg/dL or 2 hours postprandial and random blood  
18 glucose level  $\geq 200$  mg/dL or previously had been diagnosed by a doctor; while ISH was  
19 determined based on systolic blood pressure  $\geq 140$  mmHg and diastolic blood pressure  $< 90$   
20 mmHg. We also observed the subject's characteristics, such as demography, lipid profile, and  
21 subject's compliance. Data were then analyzed using Chi-square and Binary logistic  
22 regression. Study involved 3,911 DM subjects, revealed the overall prevalence of ISH 17.5%.  
23 Age category of 35-44 years old (POR= 10.80; 95%CI: 2.595-44.957), 45-54 years old  
24 (POR=22.81; 95%CI: 5.616-92.677), 55-64 years old (POR=46.12; 95% CI: 11.393-  
25 186.720); 65-74 years old (POR= 81.82; 95% CI: 20.110-332.868);  $\geq 75$  years old (POR=  
26 109.64; 95% CI: 26.373-455.789), low HDL cholesterol (POR= 0,80; 95% CI: 0.653-0.972);  
27 duration of DM (POR= 1.73; 95% CI: 1.257-2.389) were associated with the ISH. The  
28 prevalence of ISH among DM subjects was 17.5%. Older DM subjects, low HDL cholesterol,  
29 and duration of DM were associated with the ISH, suggesting that modification lipid profile,  
30 especially the HDL cholesterol level, is an important measure to delay ISH in elderly and  
31 long-duration DM subjects.

32

33 *Keywords:* diabetes, isolated systolic hypertension, prevalence, risk factor, Indonesia

## 34 Introduction

35 International Diabetes Federation reports 463 million people globally, and 10.7  
36 million people in Indonesia living with diabetes placing Indonesia in the 7<sup>th</sup> rank among  
37 countries for the number of adults with diabetes [1]. Hypertension is the most frequent  
38 comorbidity for diabetes [2–4]. Both hypertension and diabetes are the major risk factors for  
39 cardiovascular diseases due to the vascular mechanism [5]. Hypertension is associated with  
40 30% of death and 25% of cardiovascular events among diabetes mellitus (DM) subjects [6].

41 DM subjects with hypertension have seven times likely to experience end-stage renal disease  
42 and 2-4 times to get myocardial infarction and stroke [6].

43 Hypertension occurred due to the vascular resistance and increase of fluid volume [7].  
44 Vascular resistance in DM subjects is related to vascular remodeling that caused arterial  
45 stiffness, while the increase of body fluid volume is associated with resistance-induced  
46 hyperinsulinemia and hyperglycemia [7]. Isolated systolic hypertension (ISH) is the most  
47 frequent form of hypertension among the elderly [8] and the most frequent subtype of  
48 uncontrolled hypertension [9]. People with diabetes have twice higher risk to get ISH than of  
49 those without diabetes [10]. ISH reflects widespread atherosclerosis and increases stroke risk  
50 of 11% as well as an increase in all-cause mortality risk of 16% [10]. Alongside the ISH, the  
51 pulse pressure (PP) and mean arterial pressure (MAP) is the independent predictors of  
52 cardiovascular events and all-cause mortality [10–13].

53 A previous study[14] based on the hospital-based data reported that the prevalence of  
54 ISH among DM subjects was 37.4%, and age was the most related factor. Another study  
55 reported that the prevalence of ISH among DM subjects was 27.6%[15]; male, older age,  
56 obesity, and smoking were its risk factors [15,16]. A study in Indonesia reported risk factors  
57 of hypertension among DM subjects such as age, mental health disorders, obesity, physical  
58 activities, duration of diabetes, dyslipidemia, and patient compliance [17]. However, limited  
59 information regarding prevalence and risk factors of ISH among DM subjects based on  
60 population-based data. The present study aimed to explore the prevalence of ISH and its risk  
61 factors among DM subjects based on community setting study in Indonesia.

## 62 **Materials and Methods**

### 63 **Design and study population**

64 This cross-sectional study extracted secondary data from the basic health survey  
65 (Riset Kesehatan Dasar; RISKESDAS) 2018, the latest five-annual national scope cross-  
66 sectional study, conducted by the National Institute of Research and Development, Ministry  
67 of Health, the Republic of Indonesia. The survey was conducted and delivered for households  
68 systematic-randomly selected from 514 districts/cities in 34 provinces. For each province and  
69 district/city, the number of proportional census blocks was determined systematically. Three  
70 hundred households or 30.000 census blocks were then determined to be involved in the  
71 survey. Of them, 94.2 % or 282,654 households completed the questionnaire consist of  
72 1,017,290 individual subjects[18]. The study population involved subjects with DM in the  
73 RISKESDAS 2018 data. Subjects with DM were determined by fasting blood glucose level  $\geq$   
74 126 mg/dL or 2 hours postprandial and random blood glucose level  $\geq$  200 mg/dL or  
75 previously had been diagnosed by a doctor.

### 77 **Data collection**

78 Ethical clearance for the RISKESDAS 2018 study was obtained from the Ethics  
79 Committee, the National Institute of Health Research and Development (NIHRD), the  
80 Ministry of Health, Republic of Indonesia. Subject with ISH was defined as those with  
81 systolic blood pressure  $\geq$  140 mmHg and diastolic blood pressure  $<$  90 mmHg [19]. We  
82 categorized the subject as non-hypertensive when meet the criteria of optimal ( $<$ 120 mmHg  
83 and  $<$ 80 mmHg), or normal (120 mmHg-129 mmHg and/or 80-84 mmHg), or high normal  
84 (130-139 mmHg and/or 85-89 mmHg). While non ISH hypertension were categorized for  
85 grade 1-3 hypertension; grade 1 hypertension: 140-159 mmHg and/or 90-99 mmHg; grade 2  
86 hypertension: 160-179 mmHg and/or 100-109 mmHg; grade 3 hypertension:  $\geq$ 180 mmHg  
87 and or  $\geq$ 110 mmHg [19]. Based on the measurement of blood pressure, we also calculated  
88 pulse pressure (PP) and mean arterial pressure (MAP). PP was calculated as a result of the

89 formula (PP = systolic blood pressure (SBP) – diastolic blood pressure (DBP)), while the  
90 MAP was calculated as the formula of  $(MAP = \frac{SBP+2*DBP}{3})$ .

91 Secondary data acquired from RISKESDAS 2018 were age, sex, urban-rural  
92 residence status, marital status, educational level, employment status, total cholesterol level,  
93 HDL-cholesterol level, triglycerides level, history of hypertension, smoking, physical activity  
94 status, alcohol consumption, body mass index (BMI), duration of DM, type of medication,  
95 and medication compliance.

96

## 97 **Statistical analysis**

98 Characteristics of the subjects were presented as proportions since they are categorical  
99 type of data. The association between ISH status were analyzed using the Chi-square test.  
100 The p-values <0.05 were considered statistically significant. Parameters that had p-value  
101 <0.25 were then involved in the multivariate analysis using binary logistic regression. All  
102 statistical analyses were performed using the Statistical Package for the Social Sciences  
103 (SPSS) software (version 23.0 for Windows, IBM SPSS Inc., Chicago, IL).  
104

## 105 **Results**

106 Data extracted from the RISKESDAS 2018 consisted of 3,911 DM subjects that were  
107 included in the final analysis. Study population consisted of 1,289 (33%) male and 2,622  
108 (67%) female. The most frequent age category was 45-54 years old (29.3 %). More than half  
109 of the study population was live in the urban area with a low level of education and were  
110 employed in various sectors. Most of the study population had lower total cholesterol levels,  
111 lower high-density lipoprotein (HDL) cholesterol level, higher low-density lipoprotein (LDL)  
112 cholesterol level, and lower triglyceride levels. Most of them had a history of hypertension,  
113 non-smoking, active physical activity, and fair medication compliance. The detailed subjects'  
114 characteristics are presented in Table 1.

115 Table 1. Subjects' characteristics


<b>Variable</b>	<b>n</b>	<b>%</b>
<b>Age category (years old)</b>		
≥ 75	167	4.3
65-74	502	12.8
55-64	1098	28.1
45-54	1146	29.3
35-44	668	17.1
15-34	330	8.4
<b>Sex</b>		
Female	2622	67
Male	1289	33
<b>Residence status</b>		
Urban	2057	52.6
Rural	1854	47.4
<b>Marital status</b>		
Un-married	147	3.8
Married	3764	96.2
<b>Educational level</b>		
Primary high school	3006	76.9

Secondary high school or above	905	23.1
<b>Employment status</b>		
Un-employed	1639	41.9
Employed	2272	58.1
<b>Total Cholesterol level</b>		
≥200 mg/dL	1832	46.8
<200 mg/dL	2079	53.2
<b>HDL level</b>		
≥40 mg/dL	1140	29.1
<40 mg/dL	2771	70.9
<b>LDL level</b>		
≥100 mg/dL	3296	84.3
<100 mg/dL	615	15.7
<b>Triglyceride</b>		
≥150 mg/dL	1612	41.2
<150 mg/dL	2299	58.8
<b>History of hypertension</b>		
Yes	1350	34.5
No	2561	65.5
<b>Smoking</b>		
Yes	1002	25.6
No	2909	74.4
<b>Physical activity status</b>		
Sedentary	605	15.5
Active	3306	84.5
<b>Alcohol consumption</b>		
Yes	37	0.9
No	3874	99.1
<b>BMI</b>		
Obese	1262	32.3
Overweight	603	15.4
Normal	1767	45.2
Underweight	164	4.2
Severe Underweight	115	2.9
<b>Duration of DM</b>		
>5 years	1867	47.7
<5 years	2044	52.3
<b>Type of DM medication</b>		
No medication	830	21.2
OHD+insulin	828	21.2
Insulin	770	19.7
OHD	1483	37.9
<b>Medication compliance</b>		
No	1625	41.5
Yes	2286	58.5

116 BMI: body mass index; HDL=high-density lipoprotein; LDL=low-density lipoprotein


117

118 Based on the result of blood pressure measurement, a total of 1,903 (48.7%) subjects  
119 were categorized as normal, while the rest of 2,008 (51.3%) were categorized as  
120 hypertension, whether grade 1,2,3 or ISH. ISH was the most frequent form of hypertension in  
121 the study population (Fig. 1). The highest mean MAP was in non-ISH hypertension group,  
122 while the highest mean PP was in the ISH group (Fig. 2)



123  
124  
125  
126  
127

Figure 1. Frequency of blood pressure classification among DM subjects  
Optimal: <120 and <80; Normal: 120-129 and/or 80-84; High normal: 130-139 and/or 85-89; Grade I hypertension: 140-159 and/or 90-99; Grade II hypertension: 160-179 and or 100-109; Grade III hypertension:  $\geq 180$  and or  $\geq 110$ ; Isolated systolic hypertension (ISH):  $\geq 140$  and <90



128  
129  
130

Figure 2. Mean arterial pressure (MAP) and pulse pressure based on hypertension classification.

131

ISH: isolated systolic hypertension

132

133

134

135

136

137

138

139

140

141

Of the total 3,911 study population of DM subjects, 685 subjects were identified as ISH, indicated that the prevalence of ISH was 17.5%. Table 2 identified variables associated with the ISH. Older subjects, low educational level, high total cholesterol level, low HDL level, active physical activity, obese, duration of DM, and type of medication were associated with the ISH status among DM subjects. These variables, combined with other variables that  $p \leq 0.25$ , i.e., employment status, LDL level, triglyceride, history of hypertension, alcohol consumption, and medication compliance, continued to be involved in the Binary logistic regression, and the final model of regression showed in Table 3.

Table 2. Subjects' characteristics based on ISH status

Parameter	ISH			p <sup>*</sup>	POR	95%CI	
	Yes n(%)	No n(%)	Total n(%)			Lower	Uper
<b>Age (years old)</b>							
≥75	70 (41.9)	97 (58.1)	167	0.001	69.16	17.172	278.560
65-74	174 (34.7)	328 (65.3)	502	0.001	57.19	14.289	228.905
55-64	253 (23)	845 (77)	1098	0.001	38.02	9.508	152.020
45-54	145 (12.7)	1001 (87.3)	1146	0.001	20.88	5.200	83.822
35-44	41 (6.1)	627 (93.9)	668	0.001	10.13	2.465	41.612
15-34	2 (0.6)	328 (99.4)	330	Reference	1		
<b>Sex</b>							
Female	451 (17.2)	2171 (82.8)	2622	0.489	0.95	0.821	1.093
Male	234 (18.2)	1055 (81.8)	1289				
<b>Residence status</b>							
Urban	370 (18)	1687 (82)	2057	0.437	1.06	0.924	1.214
Rural	315 (17)	1539 (83)	1854				
<b>Marital status</b>							
Un-married	23 (15.6)	124 (84.4)	147	0.619	0.89	0.607	1.303
Married	662 (17.6)	3102 (82.4)	3764				
<b>Education level</b>							
Low	553 (18.4)	2453 (81.6)	3006	0.009	1.26	1.059	1.502
High	132 (14.6)	773 (85.4)	905				
<b>Employment status</b>							
Un-employed	308 (18.8)	1331 (81.2)	1639	0.081	1.13	0.988	1.298
Employed	377 (16.6)	1895 (83.4)	2272				
<b>Total Cholesterol level</b>							
≥200 mg/dL	345 (18.8)	1487 (81.2)	1832	0.046	1.15	1.005	1.319
<200 mg/dL	340 (16.4)	1739 (83.6)	2079				
<b>HDL level</b>							
≥40 mg/dL	169 (14.8)	971 (85.2)	1140	0.005	0.80	0.679	0.934
<40 mg/dL	516 (18.6)	2255 (81.4)	2771				
<b>LDL level</b>							
≥100 mg/dL	591 (17.9)	2705 (2.1)	3296	0.127	1.17	0.961	1.433
<100 mg/dL	94 (15.3)	521 (84.7)	615				
<b>Triglyceride</b>							
≥150 mg/dL	261 (16.2)	1351 (83.8)	1612	0.075	0.88	0.763	1.010
<150 mg/dL	424 (18.4)	1875 (81.6)	2299				
<b>History of hypertension</b>							
Yes	250 (18.5)	1100 (81.5)	1350	0.248	1.09	0.947	1.255

No	435 (17)	2126 (83)	2561				
<b>Smoking</b>							
Yes	182 (18.2)	820 (81.8)	1002	0.563	1.05	0.901	1.225
No	503 (17.3)	2406 (82.7)	2909				
<b>Physical activity status</b>							
Sedentary	131 (21.7)	474 (78.3)	605	0.004	1.29	1.091	1.531
Active	554 (16.8)	2752 (83.2)	3306				
<b>Alcohol consumption</b>							
Yes	2 (5.4)	35 (94.6)	37	0.084	0.31	0.080	1.182
No	683 (17.6)	3191 (82.4)	3874				
<b>BMI</b>							
Obese	165 (13.1)	1097 (86.9)	1262	0.003	0.557	0.389	0.798
Overweight	91 (15.1)	512 (84.9)	603	0.037	0.643	0.439	0.940
Normal	368 (20.8)	1399 (79.2)	1767	0.576	0.887	0.630	1.249
Underweight	34 (20.7)	130 (79.3)	164	0.690	0.883	0.566	1.379
Severe underweighth	27 (23.5)	88 (76.5)	115	Reference			
<b>Duration of DM</b>							
>5 years	469 (25.1)	1398 (74.9)	1867	0.001	2.38	2.049	2.758
<5 years	216 (10.6)	1828 (89.4)	2044				
<b>Type of DM medication</b>							
No medication	235 (28.3)	595 (71.7)	830	0.001	2.09	1.766	2.471
OHD+insulin	158 (19.1)	670 (80.9)	828	0.001	1.41	1.164	1.703
Insulin	91 (11.8)	679 (88.2)	770	0.261	0.87	0.692	1.099
OHD	201 (13.6)	1282 (86.4)	1483	Reference	1		
<b>Medication compliance</b>							
No	307 (18.9)	1318 (81.1)	1625	0.062	1.14	0.997	1.310
Yes	378 (16.5)	1908 (83.5)	2286				

142 \*Chi-square test

143 HDL: high density lipoprotein; LDL: low density lipoprotein; OHD: oral hypoglycaemic drugs; POR:  
144 prevalence odds ratio

145

146 We found that older subjects, low HDL cholesterol (prevalence odds ratio;  
147 POR=0.80; 95% CI: 0.653-0.972), and duration of DM (POR=1.73; 95% CI: 1.257-2.389),  
148 all together were associated with the ISH. Subjects with the older age category tend to get  
149 higher POR, i.e., 10.80, 22.81, 46.81, 81.82, and 109.64 for the age category of 35-44, 45-54,  
150 55-64, 65-74, and  $\geq 75$  years old, respectively (Table 3).

151

152 Table 3. Binary logistic regression of ISH risk factors among DM subjects

Variables	p	POR	95% CI.	
Age (years old)				
$\geq 75$	<b>0.001</b>	109.64	26.373	455.789
65-74	0.001	81.82	20.110	332.868
55-64	0.001	46.12	11.393	186.720
45-54	0.001	22.81	5.616	92.677
35-44	0.001	10.80	2.595	44.957
High HDL cholesterol	<b>0.025</b>	0.80	0.653	0.972
History of hypertension	0.070	1.183	0.986	1.418
<b>BMI</b>				
Obese	0.331	0.769	0.453	1.306
Overweight	0.493	0.825	0.475	1.431



Normal	0.369	1.241	0.775	1.987
Underweight	0.857	0.946	0.520	1.722
Duration of DM	<b>0.001</b>	1.73	1.257	2.389

153 BMI: body mass index; HDL: high density lipoprotein; POR: prevalence odds ratio  
154

## 155 Discussion

156 The present study reported a national scope, population-based cross-sectional study  
157 that involved 3,911 DM subjects in Indonesia. Of them, 685 experienced ISH, indicated that  
158 the prevalence of ISH among DM subjects in this population study was 17.5%. The  
159 prevalence of ISH among DM subjects in Indonesia based on this study population was lower  
160 than the prevalence of ISH in Ghana, i.e., 37.4% based on the out-patient diabetes clinic in  
161 the teaching hospital of Tamale [14]. Similarly, as a hospital-based study, a study in Jimma,  
162 Ethiopia, found that the prevalence of ISH among DM patients was 27.6% [15]. A  
163 population-based study in district Chiem Hoa, Vietnam, observed the general elderly  
164 population aged >60 years old found a prevalence of 22.9 % [20]. Another national  
165 population-based study in the USA revealed that the prevalence of ISH in the general  
166 population was 9.4% [21]. A similar result as the current study reported by a hospital-based  
167 cohort study in Italy that observed ISH among type 2 DM and found a prevalence of 20.3 %  
168 [22].

169 The present study also added evidence that DM subjects with older age, i.e.,  $\geq 75$   
170 years old, was the most influential risk factor of ISH. This finding is in accordance with the  
171 previous cohort study in Italy which concluded that the mean age of type 2 DM subjects  
172 experienced ISH was 74.3 years old [22]. On the other hand, a study in Ethiopia reported that  
173 DM subjects aged  $\geq 60$  years old were the protective factor for ISH, while the age category of  
174 47-55 years old was the risk factor with the highest OR, i.e., 2.63 [15]. Similarly, the study in  
175 Ghana showed the most frequent ISH in the DM subjects aged 50-69 years old [14].  
176 Regarding the study population, a study in Italy and Ethiopia comparing ISH to non-ISH,  
177 including other forms of hypertension, while a study in Ghana comparing ISH to normal  
178 subjects [14,15,22]. The previous review concluded that ISH affects 10-20% of the elderly,  
179 systolic blood pressure increase with age, while diastolic blood pressure rises until the age of  
180 50 years and then decreases after that [23]. Increase in blood pressure with age is mostly  
181 associated with arterial stiffness. Degenerative processes such as calcification and alteration  
182 of arteriosclerotic structure play a pivotal role in the formation of large artery stiffness as well  
183 as in the small vessels. Small vessel stiffness leads to the condition of peripheral vascular  
184 resistance that influences the increase of both systolic and diastolic blood pressure. The  
185 existence of large artery stiffness increases systolic blood pressure and, conversely, decreases  
186 diastolic blood pressure. The acceleration of large artery stiffness after 50 years old lead to  
187 the steeper increase of systolic blood pressure that caused the ISH condition [24].

188 Lipid profile leads to the process of endothelial dysfunction that affects blood  
189 pressure. HDL cholesterol tends to have inversely associated with hypertension, while non-  
190 HDL cholesterol has a positive association [25]. The present study found that HDL was  
191 inversely associated with the ISH, while in the bivariate analysis, total cholesterol showed a  
192 positive association with ISH. High HDL level, i.e.,  $\geq 40$  mg/dL, was concluded as the  
193 protective factor for ISH in this study. This finding was in accordance with the Physician  
194 Health Study that reported the highest quartile of HDL level, i.e.,  $>53$  mg/dL had the lowest  
195 adjusted-RR (0.68) compared to the other quartile [26]. A study in China also reported that  
196 HDL level was inversely related to the blood pressure as well as brachial-ankle pulse-wave  
197 velocity, a marker of arterial stiffness development [25]. The atherosclerotic formation



198 structure of the vessels also influenced by the oxidative activity of LDL cholesterol that is  
199 also inhibited by HDL [27,28]. However, a previous study in Japan reported a positive  
200 correlation between HDL and hypertension in apparently healthy people [29]. Another study  
201 revealed that a positive association between HDL and hypertension occurred in the subjects  
202 with high-level circulation CD34-positive cells, a bone marrow-derived endothelial  
203 progenitor. The level of circulating CD-34 increases as a response of the endothelial damage,  
204 therefore masking the role of HDL as endothelial protective in healthy subjects [30].

205 The current study also found that duration of DM, i.e., more than five years, was  
206 significantly associated with ISH, PR=1.73 (95% CI: 1.257-2.389). This finding adds the  
207 evidence that previously reported elsewhere that revealed diabetes duration and insulin  
208 treatment status were the independent predictor of ISH [31]. The progression and duration of  
209 diabetes increase complications. Duration of diabetes is associated with arterial stiffness,  
210 while arterial stiffness plays a pivotal role in ISH [31]. The gradation of DM duration as a  
211 dose-response relationship with hypertension was also described in the previous study [32].  
212 These findings strengthen the hypothesis that diabetes precedes arterial stiffness that caused  
213 ISH; however, another study found that onset on diabetes and brachial-ankle pulse wave  
214 velocity occurred simultaneously after a longitudinal observation indicates conversely  
215 condition [33]. Indeed, there are roles of multifactor that contributed to the arterial stiffness  
216 as a major cause of ISH. Arterial stiffness is a result of degenerative processes in the  
217 extracellular matrix of elastic arteries caused by aging and many other risk factors [34].

218 The final model of Binary logistic regression in this study involved a history of  
219 hypertension; however, the p-value did not meet to be considered significant. The previous  
220 history of hypertension describes the condition of individuals who tend to have a genetic  
221 predisposition [35]. Hypertension is the form of the complex trait that involved multiple  
222 organs and pathways [35,36]. Comprehensive understanding of genomics, epigenomics,  
223 metabolomics, proteomics, and transcriptomics of blood pressure plays a pivotal role in the  
224 context of the previous history of hypertension [35]. Further study that observed the detailed  
225 genetic role should be conducted to elucidate the novel hypertension pathophysiology and  
226 dissect and characterize the disorder's mechanism.

227 It is well established that obesity is associated with ISH [37–39]. Obesity affects the  
228 process of inflammation, cell adhesion, and coagulation that impact in the arterial stiffness  
229 [38,40]. Obesity is also related to the insulin and leptin resistance that contributes to sodium  
230 retention with concomitant cardiac output [39]. However, in this study, BMI did not  
231 significantly associate with ISH, although involved in the final model. It must be considered  
232 that the role of BMI measurement alone is inadequate for accurately predict the disease  
233 progression in DM subjects [41]. Other parameters such as body composition, total adipose  
234 mass, visceral adiposity–accumulation of intra-abdominal fat, and muscle mass should be  
235 analyzed to describe the current condition of DM subjects [41–43].

236

## 237 **Conclusions**

238 The prevalence of ISH among Indonesian DM subjects in the present study was  
239 17.5%. Older DM subjects, low HDL cholesterol, and duration of DM were associated with  
240 the ISH, suggesting that modify lipid profile, especially HDL cholesterol level, is a needful  
241 measure to delay ISH in older and duration DM subjects.

## 242 **Data Availability**

243 The data used in this study are available from the corresponding author Mahalul Azam upon  
244 request through the email address [mahalul.azam@mail.unnes.ac.id](mailto:mahalul.azam@mail.unnes.ac.id). The data set was  
245 accessed from the RISKESDAS (Riset Kesehatan Dasar); a five-annual national basic health  
246 survey that conducted and supported by the National Institute of Health Research and  
247 Development (NIHRD), Ministry of Health, the Republic of Indonesia. The protocol and  
248 reports of the RISKESDAS is published on [https://www.litbang.kemkes.go.id/laporan-riset-](https://www.litbang.kemkes.go.id/laporan-riset-kesehatan-dasar-riskesdas/)  
249 [kesehatan-dasar-riskesdas//](https://www.litbang.kemkes.go.id/laporan-riset-kesehatan-dasar-riskesdas/)

## 250 **Conflicts of Interest**

251 The authors have declared that there is no conflict of interest exists.

252  
253

## 254 **Funding Statement**

255 Research Grant of Faculty of Sports Science, Universitas Negeri Semarang. [Grant ID:  
256 36.4.5/UN37/PPK.4.6/2020].

## 257 **Acknowledgments**

258 This study was supported by the Faculty of Sports Science, Universitas Negeri Semarang,  
259 Indonesia [Grant ID: 36.4.5/UN37/PPK.4.6/2020]. The RISKESDAS (Riset Kesehatan  
260 Dasar); a five-annual national basic health survey is conducted and supported by the National  
261 Institute of Health Research and Development (NIHRD), Ministry of Health, the Republic of  
262 Indonesia. The manuscript was prepared using a limited access data set obtained from the  
263 NIHRD and does not reflect the opinions or views of RISKESDAS and NIHRD. The authors  
264 thank the RISKESDAS investigators for granting permission to use their data set for the  
265 current study. The protocol and reports of the RISKESDAS is published on  
266 [https://www.litbang.kemkes.go.id/laporan-riset-kesehatan-dasar-riskesdas//](https://www.litbang.kemkes.go.id/laporan-riset-kesehatan-dasar-riskesdas/)

267

## 268 **References**

- 269 [1] International Diabetes Federation, IDF Diabetes atlas 9th edition, Brussel, Belgium,  
270 2019. <https://www.diabetesatlas.org>.
- 271 [2] B. Tesfaye, A. Alebel, A. Gebrie, A. Zegeye, C. Tesema Leshargie, A. Ferede, H.  
272 Abera, K. Alam, Diabetes Mellitus and Its Association with Hypertension in Ethiopia:  
273 A Systematic Review and Meta-Analysis., *Diabetes Res. Clin. Pract.* 156 (2019)  
274 107838. <https://doi.org/10.1016/j.diabres.2019.107838>.
- 275 [3] A.D. Colosia, R. Palencia, S. Khan, Prevalence of hypertension and obesity in patients  
276 with type 2 diabetes mellitus in observational studies: a systematic literature review.,

- 277 diabetes. *Metab. Syndr. Obes.* 6 (2013) 327–338.  
278 <https://doi.org/10.2147/DMSO.S51325>.
- 279 [4] C.T. Nguyen, N.M. Pham, A.H. Lee, C.W. Binns, Prevalence of and Risk Factors for  
280 Type 2 Diabetes Mellitus in Vietnam: A Systematic Review., *Asia-Pacific J. Public*  
281 *Heal.* 27 (2015) 588–600. <https://doi.org/10.1177/1010539515595860>.
- 282 [5] J.R. Petrie, T.J. Guzik, R.M. Touyz, Diabetes, Hypertension, and Cardiovascular  
283 Disease: Clinical Insights and Vascular Mechanisms., *Can. J. Cardiol.* 34 (2018) 575–  
284 584. <https://doi.org/10.1016/j.cjca.2017.12.005>.
- 285 [6] G. Chen, F.A. McAlister, R.L. Walker, B.R. Hemmelgarn, N.R.C. Campbell,  
286 Cardiovascular outcomes in framingham participants with diabetes: The importance of  
287 blood pressure, hypertension. 57 (2011) 891–897.  
288 <https://doi.org/10.1161/HYPERTENSIONAHA.110.162446>.
- 289 [7] M. Ohishi, Hypertension with diabetes mellitus: physiology and pathology.,  
290 *Hypertens. Res.* 41 (2018) 389–393. <https://doi.org/10.1038/s41440-018-0034-4>.
- 291 [8] C. Bavishi, S. Goel, F.H. Messerli, Isolated Systolic Hypertension: An Update After  
292 SPRINT., *Am. J. Med.* 129 (2016) 1251–1258.  
293 <https://doi.org/10.1016/j.amjmed.2016.08.032>.
- 294 [9] S.S. Franklin, P. Lapuerta, G.J. L'Italien, N.D. Wong, M.J. Jacobs, Predominance of  
295 Isolated Systolic Hypertension Among Middle-Aged and Elderly US Hypertensives,  
296 *Hypertension.* 37 (2012) 869–874. <https://doi.org/10.1161/01.hyp.37.3.869>.
- 297 [10] I. Os, H. Gudmundsdottir, S.E. Kjeldsen, S. Oparil, Treatment of isolated systolic  
298 hypertension in diabetes mellitus type 2., *diabetes. Obes. Metab.* 8 (2006) 381–387.  
299 <https://doi.org/10.1111/j.1463-1326.2005.00523.x>.
- 300 [11] N. Madan, A.K. Lee, K. Matsushita, R.C. Hoogeveen, C.M. Ballantyne, E. Selvin,  
301 J.W. McEvoy, Relation of Isolated Systolic Hypertension and Pulse Pressure to High-  
302 Sensitivity Cardiac Troponin-T and N-Terminal pro-B-Type Natriuretic Peptide in  
303 Older Adults (from the Atherosclerosis Risk in Communities Study)., *Am. J. Cardiol.*  
304 124 (2019) 245–252. <https://doi.org/10.1016/j.amjcard.2019.04.030>.
- 305 [12] S. Selvaraj, P.G. Steg, Y. Elbez, E. Sorbets, L.J. Feldman, K.A. Eagle, E.M. Ohman, J.  
306 Blacher, D.L. Bhatt, Pulse Pressure and Risk for Cardiovascular Events in Patients  
307 With Atherothrombosis: From the REACH Registry., *J. Am. Coll. Cardiol.* 67 (2016)  
308 392–403. <https://doi.org/10.1016/j.jacc.2015.10.084>.
- 309 [13] G.J. Winston, W. Palmas, J. Lima, J.F. Polak, A.G. Bertoni, G. Burke, J. Eng, R.  
310 Gottesman, S. Shea, Pulse pressure and subclinical cardiovascular disease in the multi-

- 311 ethnic study of atherosclerosis., *Am. J. Hypertens.* 26 (2013) 636–642.  
312 <https://doi.org/10.1093/ajh/hps092>.
- 313 [14] R.K.D. Ephraim, A.R. Saasi, E.O. Anto, P. Adoba, Determinants of isolated systolic  
314 hypertension among diabetic patients visiting the diabetic clinic at the Tamale  
315 Teaching Hospital, Northern Ghana., *Afr. Health Sci.* 16 (2016) 1151–1156.  
316 <https://doi.org/10.4314/ahs.v16i4.33>.
- 317 [15] B. Dagneu, Y. Yeshaw, Predictors of isolated systolic hypertension among type 2  
318 diabetes mellitus patients in Jimma University Specialized Hospital, Southwest  
319 Ethiopia, *BMC Res. Notes.* 12 (2019) 1–7. [https://doi.org/10.1186/s13104-019-4550-](https://doi.org/10.1186/s13104-019-4550-3)  
320 3.
- 321 [16] R. Grebla, C. Rodriguez, L. Borrell, T. Pickering, Prevalence and determinants of  
322 isolated systolic hypertension among young adults., *J. Am. Soc. Hypertens.* 28 (2010)  
323 15–23. <https://doi.org/10.1097/HJH.0b013e328331b7ff>.Prevalence.
- 324 [17] M. Sihombing, Faktor yang Berhubungan dengan Hipertensi pada Penduduk Indonesia  
325 yang Menderita Diabetes Melitus (Data Riskesdas 2013), *Bul. Penelit. Kesehat.* 45  
326 (2017) 53–64. <https://doi.org/10.22435/bpk.v45i1.5730.53-64>.
- 327 [18] Badan Penelitian dan Pengembangan Kesehatan, Laporan Nasional Riset Kesehatan  
328 Dasar: RISKESDAS (Indonesia Basic Health Survey) tahun 2018, 2018.  
329 [http://labmandat.litbang.kemkes.go.id/images/download/laporan/RKD/2018/Laporan\\_](http://labmandat.litbang.kemkes.go.id/images/download/laporan/RKD/2018/Laporan_Nasional_RKD2018_FINAL.pdf)  
330 [Nasional\\_RKD2018\\_FINAL.pdf](http://labmandat.litbang.kemkes.go.id/images/download/laporan/RKD/2018/Laporan_Nasional_RKD2018_FINAL.pdf).
- 331 [19] A.F. Members, G. Mancina, R. Fagard, K. Narkiewicz, J. Redon, A. Zanchetti, M.  
332 Böhm, T. Christiaens, R. Cifkova, G. De Backer, A. Dominiczak, M. Galderisi, D.E.  
333 Grobbee, T. Jaarsma, P. Kirchhof, S.E. Kjeldsen, S. Laurent, A.J. Manolis, P.M.  
334 Nilsson, L.M. Ruilope, R.E. Schmieder, P.A. Simes, P. Sleight, M. Viigimaa, B.  
335 Waeber, F. Zannad, E.S.H.S. Council, J. Redon, A. Dominiczak, K. Narkiewicz, P.M.  
336 Nilsson, M. Burnier, M. Viigimaa, E. Ambrosioni, M. Caulfield, A. Coca, M.H. Olsen,  
337 R.E. Schmieder, C. Tsioufis, P. van de Borne, E.S.C.C. for P.G. (CPG), J.L.  
338 Zamorano, S. Achenbach, H. Baumgartner, J.J. Bax, H. Bueno, V. Dean, C. Deaton, C.  
339 Erol, R. Fagard, R. Ferrari, D. Hasdai, A.W. Hoes, P. Kirchhof, J. Knuuti, P. Kolh, P.  
340 Lancellotti, A. Linhart, P. Nihoyannopoulos, M.F. Piepoli, P. Ponikowski, P.A. Simes,  
341 J.L. Tamargo, M. Tendera, A. Torbicki, W. Wijns, S. Windecker, D. Reviewers, D.L.  
342 Clement, A. Coca, T.C. Gillebert, M. Tendera, E.A. Rosei, E. Ambrosioni, S.D.  
343 Anker, J. Bauersachs, J.B. Hitij, M. Caulfield, M. De Buyzere, S. De Geest, G.A.  
344 Derumeaux, S. Erdine, C. Farsang, C. Funck-Brentano, V. Gerc, G. Germano, S.

- 345 Gielen, H. Haller, A.W. Hoes, J. Jordan, T. Kahan, M. Komajda, D. Lovic, H.  
346 Mahrholdt, M.H. Olsen, J. Ostergren, G. Parati, J. Perk, J. Polonia, B.A. Popescu, Ž.  
347 Reiner, L. Rydén, Y. Sirenko, A. Stanton, H. Struijker-Boudier, C. Tsoufifis, P. van de  
348 Borne, C. Vlachopoulos, M. Volpe, D.A. Wood, 2013 ESH/ESC Guidelines for the  
349 management of arterial hypertension: The Task Force for the management of arterial  
350 hypertension of the European Society of Hypertension (ESH) and of the European  
351 Society of Cardiology (ESC), *Eur. Heart J.* 34 (2013) 2159–2219.  
352 <https://doi.org/10.1093/eurheartj/eh151>.
- 353 [20] N. Bui Van, L. Vo Hoang, T. Bui Van, H.N.S. Anh, H.T. Minh, K. Do Nam, T.N. Tri,  
354 P.L. Show, V.T. Nga, D.B. Thimiri Govinda Raj, D.-T. Chu, Prevalence and Risk  
355 Factors of Hypertension in the Vietnamese Elderly., *High Blood Press. Cardiovasc.*  
356 *Prev. Off. J. Ital. Soc. Hypertens.* 26 (2019) 239–246. [https://doi.org/10.1007/s40292-](https://doi.org/10.1007/s40292-019-00314-8)  
357 [019-00314-8](https://doi.org/10.1007/s40292-019-00314-8).
- 358 [21] X. Liu, C.J. Rodriguez, K. Wang, Prevalence and trends of isolated systolic  
359 hypertension among untreated adults in the United States., *J. Am. Soc. Hypertens.* 9  
360 (2015) 197–205. <https://doi.org/10.1016/j.jash.2015.01.002>.
- 361 [22] S. Bo, G. Ciccone, G. Grassi, R. Gancia, R. Rosato, F. Merletti, G. Pagano, Isolated  
362 systolic hypertension in a cohort of type 2 diabetic patients., *Nutr. Metab. Cardiovasc.*  
363 *Dis.* 14 (2004) 157–161. [https://doi.org/10.1016/s0939-4753\(04\)80036-x](https://doi.org/10.1016/s0939-4753(04)80036-x).
- 364 [23] L. Thijs, E. Den Hond, T. Nawrot, J.A. Staessen, Prevalence, pathophysiology and  
365 treatment of isolated systolic hypertension in the elderly, *Expert Rev. Cardiovasc.*  
366 *Ther.* 2 (2004) 761–769. <https://doi.org/10.1586/14779072.2.5.761>.
- 367 [24] E. Pinto, Blood pressure and ageing, *Postgrad. Med. J.* 83 (2007) 109–114.  
368 <https://doi.org/10.1136/pgmj.2006.048371>.
- 369 [25] B. Zhan, X. Huang, J. Wang, X. Qin, J. Zhang, J. Cao, Y. Song, L. Liu, P. Li, R. Yang,  
370 Y. Wu, Q. Wu, Y. Zhang, J. Li, Y. Huo, B. Wang, X. Xu, H. Bao, X. Cheng,  
371 Association Between Lipid Profiles and Arterial Stiffness in Chinese Patients With  
372 Hypertension: Insights From the CSPPT, *Angiology.* 70 (2019) 515–522.  
373 <https://doi.org/10.1177/0003319718823341>.
- 374 [26] HR O., SH D., M. Jing, BJ E., SM J., MG J., Dyslipidemia and the Risk of Incident  
375 Hypertension in Men, *Hypertension.* 47 (2006) 45–50.  
376 <https://doi.org/10.1161/01.HYP.0000196306.42418.0e>.
- 377 [27] F. Brites, M. Martin, I. Guillas, A. Kontush, Antioxidative activity of high-density  
378 lipoprotein (HDL): Mechanistic insights into potential clinical benefit., *BBA Clin.* 8

- 379 (2017) 66–77. <https://doi.org/10.1016/j.bbacli.2017.07.002>.
- 380 [28] R. Puri, S.E. Nissen, M. Shao, M.B. Elshazly, Y. Kataoka, S.R. Kapadia, E.M. Tuzcu,  
381 S.J. Nicholls, Non-HDL Cholesterol and Triglycerides: Implications for Coronary  
382 Atheroma Progression and Clinical Events, *Arterioscler. Thromb. Vasc. Biol.* 36  
383 (2016) 2220–2228. <https://doi.org/10.1161/ATVBAHA.116.307601>.
- 384 [29] E. Oda, R. Kawai, High-density lipoprotein cholesterol is positively associated with  
385 hypertension in apparently healthy Japanese men and women, *Br. J. Biomed. Sci.* 68  
386 (2011) 29–33. <https://doi.org/10.1080/09674845.2011.11732838>.
- 387 [30] Y. Shimizu, S. Sato, J. Koyamatsu, H. Yamanashi, M. Nagayoshi, K. Kadota, SY.  
388 Kawashiri, T. Maeda, Association between high-density lipoprotein-cholesterol and  
389 hypertension in relation to circulating CD34-positive cell levels, *J. Physiol. Anthropol.*  
390 36 (2017) 1–7. <https://doi.org/10.1186/s40101-017-0143-9>.
- 391 [31] H. Smulyan, A. Lieber, M.E. Safar, Hypertension, Diabetes Type II, and Their  
392 Association: Role of Arterial Stiffness., *Am. J. Hypertens.* 29 (2016) 5–13.  
393 <https://doi.org/10.1093/ajh/hpv107>.
- 394 [32] M. Berraho, Y. El Achhab, A. Benslimane, K. El Rhazi, M. Chikri, C. Nejjari,  
395 Hypertension and type 2 diabetes: a cross-sectional study in Morocco (EPIDIAM  
396 Study)., *Pan Afr. Med. J.* 11 (2012) 52.
- 397 [33] Y. Zhang, P. He, Y. Li, Y. Zhang, J. Li, M. Liang, G. Wang, G. Tang, Y. Song, B.  
398 Wang, C. Liu, L. Liu, Y. Cui, X. Wang, Y. Huo, X. Xu, X. Qin, Positive association  
399 between baseline brachial–ankle pulse wave velocity and the risk of new-onset  
400 diabetes in hypertensive patients, *Cardiovasc. Diabetol.* 18 (2019) 111.  
401 <https://doi.org/10.1186/s12933-019-0915-0>.
- 402 [34] C. Palombo, M. Kozakova, Arterial stiffness, atherosclerosis and cardiovascular risk:  
403 Pathophysiologic mechanisms and emerging clinical indications., *Vascul. Pharmacol.*  
404 77 (2016) 1–7. <https://doi.org/10.1016/j.vph.2015.11.083>.
- 405 [35] D.K. Arnett, S.A. Claas, Omics of Blood Pressure and Hypertension., *Circ. Res.* 122  
406 (2018) 1409–1419. <https://doi.org/10.1161/CIRCRESAHA.118.311342>.
- 407 [36] M.L. Lindsey, M. Mayr, A. V Gomes, C. Delles, D.K. Arrell, A.M. Murphy, R.A.  
408 Lange, C.E. Costello, Y.-F. Jin, D.T. Laskowitz, F. Sam, A. Terzic, J. Van Eyk, P.R.  
409 Srinivas, Transformative Impact of Proteomics on Cardiovascular Health and Disease:  
410 A Scientific Statement From the American Heart Association., *Circulation.* 132  
411 (2015) 852–872. <https://doi.org/10.1161/CIR.0000000000000226>.
- 412 [37] S. Asgari, D. Khalili, Y. Mehrabi, S. Kazempour-Ardebili, F. Azizi, F. Hadaegh,



- 413 Incidence and risk factors of isolated systolic and diastolic hypertension: a 10 year  
414 follow-up of the Tehran Lipids and Glucose Study, *Blood Press.* 25 (2016) 177–183.  
415 <https://doi.org/10.3109/08037051.2015.1116221>.
- 416 [38] R.P. Wildman, R.H. Mackey, A. Bostom, T. Thompson, K. Sutton-Tyrrell, Measures  
417 of obesity are associated with vascular stiffness in young and older adults,  
418 *hypertension.* 42 (2003) 468–473.  
419 <https://doi.org/10.1161/01.HYP.0000090360.78539.CD>.
- 420 [39] R. and E.R. Zhang, Obesity hypertension: The effects on cardiovascular and renal  
421 systems, *Am. J. Hypertens.* 13 (2000) 1308–1314.
- 422 [40] C. Delles, E. Carrick, D. Graham, S.A. Nicklin, Utilizing proteomics to understand and  
423 define hypertension: where are we and where do we go?, *Expert Rev. Proteomics.* 15  
424 (2018) 581–592. <https://doi.org/10.1080/14789450.2018.1493927>.
- 425 [41] M. Murea, L. Lenchik, T.C. Register, G.B. Russell, J. Xu, S.C. Smith, D.W. Bowden,  
426 J. Divers, B.I. Freedman, Psoas and paraspinous muscle index as a predictor of  
427 mortality in African American men with type 2 diabetes mellitus., *J. Diabetes*  
428 *Complications.* 32 (2018) 558–564. <https://doi.org/10.1016/j.jdiacomp.2018.03.004>.
- 429 [42] E.S.A. Owusu, M. Samanta, J.E. Shaw, A. Majeed, K. Khunti, S.K. Paul, Weight loss  
430 and mortality risk in patients with different adiposity at diagnosis of type 2 diabetes: a  
431 longitudinal cohort study., *Nutr. Diabetes.* 8 (2018) 37.  
432 <https://doi.org/10.1038/s41387-018-0042-0>.
- 433 [43] S. Gullaksen, K.L. Funck, E. Laugesen, T.K. Hansen, D. Dey, P.L. Poulsen, Volumes  
434 of coronary plaque disease in relation to body mass index, waist circumference,  
435 truncal fat mass and epicardial adipose tissue in patients with type 2 diabetes mellitus  
436 and controls., *Diabetes Vasc. Dis. Res.* 16 (2019) 328–336.  
437 <https://doi.org/10.1177/1479164119825761>.
- 438